Open Veterinary Journal

Open Veterinary Journal

Peer-Reviewed Journal 
ISSN 2218-6050 (Online), ISSN 2226-4485 (Print) 

"Original Research"

HDAC2/3 inhibitor MI192 mitigates oligodendrocyte loss and reduces microglial activation upon injury: A potential role of epigenetics


Mohamed A. Al-Griw(1), Mansur E. Shmela(2), Mohamed M. Elhensheri(3) and Emad M. Bennour(4*)


1- Department of Histology and Genetics, Faculty of Medicine, University of Tripoli, Tripoli, Libya

2- Department of Preventive Medicine, Genetics & Animal Breeding, Faculty of Veterinary Medicine, University of Tripoli, Tripoli, Libya

3- Rostock University Medical Centre, Rostock, Germany

4- Department of Internal Medicine, Faculty of Veterinary Medicine, University of Tripoli, Tripoli, Libya

Abstract

Background: During development, oligodendrocyte (OL) lineage cells are susceptible to injury, leading to life-long clinical neurodevelopmental deficits, which lack effective treatments. Drugs targeting epigenetic modifications that inhibit histone deacetylases (HDACs) protect from many clinical neurodegenerative disorders.

Aim: This study aimed to investigate the therapeutic potential of histone deacetylase 2/3 (HDAC2/3) inhibitor MI192 on white matter (WM) pathology in a model of neonatal rat brain injury.

Methods: Wistar rats (8.5-day-old, n=32) were used to generate brain tissues. The tissues were cultured and then randomly divided into 4 groups and treated as following: group I (sham); the tissues were cultured under normoxia, group II (vehicle); DMSO only, group III (injury, INJ); the tissues were exposed to 20 minutes oxygen-glucose deprivation (OGD) insult, and group IV (INJ+MI192); the tissues were subjected to the OGD insult and then treated with the MI192 inhibitor. On culture day 10, the tissues were fixed for biochemical and histological examinations.

Results: The results showed that inhibition of HDAC2/3 activity alleviated WM pathology. Specifically, MI192 treatment significantly reduced cell death, minimized apoptosis, and mitigates the loss of the MBP+ OLs and their precursors (NG2+ OPCs). Additionally, MI192 decreased the density of reactive microglia (OX-42+). These findings demonstrate that the inhibition of HDAC2/3 activity post-insult alleviates WM pathology through mechanism(s) including preserving OL lineage cells and suppressing microglial activation.

Conclusion: The findings of this study suggest that HDAC2/3 inhibition is a rational strategy to preserve WM or reverse its pathology upon newborn brain injury.

Keywords: Brain injury, Epigenetics, MI192, Microglia, Oligodendrocytes.
Cite this paper:
Al-Griw, M.A., Shmela, M.E., Elhensheri, M.M. and Bennour, E.M. 2021. HDAC2/3 inhibitor MI192 mitigates oligodendrocyte loss and reduces microglial activation upon injury: A potential role of epigenetics. Open Vet. J. 11(3), 447-457.